Press Release

NeoGenomics Reports Revenue of $125 Million in the Second Quarter

NeoGenomics Announces Chief Executive Officer Appointment

NeoGenomics Schedules its Second Quarter 2022 Earnings Release for August 9, 2022

NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast Cancer

NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services Laboratory

NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences

NeoGenomics Appoints Lynn Tetrault Interim CEO

NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Present New Data Further Validating the Application of its RaDaR® MRD and InVisionFirst®-Lung Tests at the 2022 ASCO Annual Meeting

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients